---
schema_version: "secwatch.filing_event.v1"
accession: "0000950123-21-010437"
form_type: "8-K"
ticker: "SDGR"
cik: "0001490978"
company_name: "Schrodinger, Inc."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T12:49:50.405291+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Schrödinger Q2 revenue up 29% to $29.8M; net loss widens to $34.6M on investment spend

## Summary
- Total revenue $29.8M (+29% YoY); software revenue $24.1M (+15% YoY); drug discovery revenue $5.7M.
- Net loss $34.6M vs $3.4M loss Q2 2020, driven by fair-value adjustments and R&D investments.
- Announced global oncology collaboration with Zai Lab; eligible for up to ~$338M milestones and U.S. profit share.
- Pipeline advancing: plans to submit up to three INDs to FDA in 2022, first IND expected H1 2022.
- Full-year 2021 guidance maintained: total revenue $124M-$142M, software revenue $102M-$110M.

## SEC filing metadata
- accession: 0000950123-21-010437
- form_type: 8-K
- ticker: SDGR
- cik: 0001490978
- company_name: Schrodinger, Inc.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1490978/000095012321010437/0000950123-21-010437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1490978/000095012321010437/FINAL-sdgr-8k_20210812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950123-21-010437
- JSON: https://secwatch.observer/filing/0000950123-21-010437.json
- Plain text: https://secwatch.observer/filing/0000950123-21-010437.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.